DRUG_NAME,STRUCT_ID,TARGET_NAME,TARGET_CLASS,ACCESSION,GENE,SWISSPROT,ACT_VALUE,ACT_UNIT,ACT_TYPE,ACT_COMMENT,ACT_SOURCE,RELATION,MOA,MOA_SOURCE,ACT_SOURCE_URL,MOA_SOURCE_URL,ACTION_TYPE,TDL,ORGANISM,NEW_ID
aclarubicin,80,72 kDa type IV collagenase,Enzyme,P08253,MMP2,MMP2_HUMAN,5.0,,IC50,Concentration inhibiting Clostridium histolyticum collagenase.,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:7166
aldosterone,111,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,5.32,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
aminoquinuride,174,Matrix metalloproteinase-9,Enzyme,P14780,MMP9,MMP9_HUMAN,4.0,,IC50,Inhibition of human MMP-9 after 60 mins by FRET assay,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:7176
androstenediol,214,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,9.17,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
androstenedione,215,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,7.46,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
astemizole,249,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.218,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
bacitracin,281,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.269,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
beclometasone dipropionate,294,Matrix metalloproteinase-9,Enzyme,P14780,MMP9,MMP9_HUMAN,5.7,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:7176
budesonide,419,Matrix metalloproteinase-9,Enzyme,P14780,MMP9,MMP9_HUMAN,5.701,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",DRUG MATRIX,=,,,,,,Tchem,Homo sapiens,HGNC:7176
busulfan,438,Matrix metalloproteinase-9,Enzyme,P14780,MMP9,MMP9_HUMAN,5.283,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",DRUG MATRIX,=,,,,,,Tchem,Homo sapiens,HGNC:7176
candesartan cilexetil,475,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.48,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
cefonicid,542,Matrix metalloproteinase-9,Enzyme,P14780,MMP9,MMP9_HUMAN,5.04,,IC50,,WOMBAT-PK,=,,,,,,Tchem,Homo sapiens,HGNC:7176
cefotetan,547,72 kDa type IV collagenase,Enzyme,P08253,MMP2,MMP2_HUMAN,4.49,,IC50,,WOMBAT-PK,=,,,,,,Tchem,Homo sapiens,HGNC:7166
cefotetan,547,Catechol O-methyltransferase,Enzyme,P21964,COMT,COMT_HUMAN,4.85,,IC50,,WOMBAT-PK,=,,,,,,Tclin,Homo sapiens,HGNC:2228
cefotetan,547,Matrix metalloproteinase-9,Enzyme,P14780,MMP9,MMP9_HUMAN,4.72,,IC50,,WOMBAT-PK,=,,,,,,Tchem,Homo sapiens,HGNC:7176
cefotiam,548,Matrix metalloproteinase-9,Enzyme,P14780,MMP9,MMP9_HUMAN,4.46,,IC50,,WOMBAT-PK,=,,,,,,Tchem,Homo sapiens,HGNC:7176
cefuroxime,565,72 kDa type IV collagenase,Enzyme,P08253,MMP2,MMP2_HUMAN,4.37,,IC50,,WOMBAT-PK,=,,,,,,Tchem,Homo sapiens,HGNC:7166
cefuroxime,565,Matrix metalloproteinase-9,Enzyme,P14780,MMP9,MMP9_HUMAN,4.96,,IC50,,WOMBAT-PK,=,,,,,,Tchem,Homo sapiens,HGNC:7176
cefalotin,574,Matrix metalloproteinase-9,Enzyme,P14780,MMP9,MMP9_HUMAN,4.66,,IC50,,WOMBAT-PK,=,,,,,,Tchem,Homo sapiens,HGNC:7176
cefradine,576,Matrix metalloproteinase-9,Enzyme,P14780,MMP9,MMP9_HUMAN,5.4,,IC50,,WOMBAT-PK,=,,,,,,Tchem,Homo sapiens,HGNC:7176
chlorhexidine,597,72 kDa type IV collagenase,Enzyme,P08253,MMP2,MMP2_HUMAN,5.12,,IC50,Inhibition of human rheumatoid synovial fibroblasts gelatinase A after 30 mins by fluorescence plate reader,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:7166
chlorhexidine,597,Matrix metalloproteinase-9,Enzyme,P14780,MMP9,MMP9_HUMAN,5.12,,IC50,Inhibition of human neutrophils gelatinase B after 30 mins by fluorescence plate reader,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:7176
chloropyramine,606,Focal adhesion kinase 1,Kinase,Q05397,PTK2,FAK1_HUMAN,6.24,,Kd,Binding affinity to biotinylated human FAK FAT domain by biolayer interoferometry,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:9611
chlorpromazine,621,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,4.54,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
clomifene,700,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.979,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
clotrimazole,719,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,4.159,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
cortisone acetate,734,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,6.43,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
ciclosporin,760,Peptidyl-prolyl cis-trans isomerase B,Enzyme,P23284,PPIB,PPIB_HUMAN,8.01,,Kd,Binding affinity to human Cyclophilin B,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:9255
dacarbazine,773,Matrix metalloproteinase-9,Enzyme,P14780,MMP9,MMP9_HUMAN,6.255,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",DRUG MATRIX,=,,,,,,Tchem,Homo sapiens,HGNC:7176
danazol,779,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,8.2,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
dasatinib,785,Platelet-derived growth factor receptor beta,Kinase,P09619,PDGFRB,PGFRB_HUMAN,9.2,,Kd,Binding constant for PDGFRB kinase domain,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1421,INHIBITOR,Tclin,Homo sapiens,HGNC:8804
dasatinib,785,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,7.1,,Kd,Binding constant for EGFR(G719S) kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
daunorubicin,786,72 kDa type IV collagenase,Enzyme,P08253,MMP2,MMP2_HUMAN,5.72,,IC50,Inhibitory concentration against Clostridium histolyticum Collagenase,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:7166
prasterone,795,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,7.84,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
desogestrel,818,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,6.6,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
desoxycortone,820,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,7.38,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
dexamethasone,824,Interleukin-4,Cytokine,P05112,IL4,IL4_HUMAN,8.33,,IC50,,WOMBAT-PK,=,,,,,,Tbio,Homo sapiens,HGNC:6014
disulfiram,928,Protein-lysine 6-oxidase,Enzyme,P28300,LOX,LYOX_HUMAN,6.5,,IC50,Inhibition of recombinant human LOX expressed in HEK293 cells using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method,CHEMBL,=,,,,,,Tbio,Homo sapiens,HGNC:6664
dobutamine,937,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.256,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
dobutamine,937,Catechol O-methyltransferase,Enzyme,P21964,COMT,COMT_HUMAN,4.301,,Km,,WOMBAT-PK,=,,,,,,Tclin,Homo sapiens,HGNC:2228
docetaxel,939,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,9.086,,Kd,,WOMBAT-PK,=,,,,,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
doxorubicin,960,72 kDa type IV collagenase,Enzyme,P08253,MMP2,MMP2_HUMAN,5.96,,IC50,Inhibitory concentration against Clostridium histolyticum Collagenase,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:7166
doxycycline,961,72 kDa type IV collagenase,Enzyme,P08253,MMP2,MMP2_HUMAN,4.62,,IC50,Inhibition of human MMP2,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:7166
ebastine,977,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,6.253,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
econazole,983,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,4.489,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
econazole,983,Matrix metalloproteinase-9,Enzyme,P14780,MMP9,MMP9_HUMAN,5.155,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",DRUG MATRIX,=,,,,,,Tchem,Homo sapiens,HGNC:7176
entacapone,1018,Catechol O-methyltransferase,Enzyme,P21964,COMT,COMT_HUMAN,9.523,,Ki,,SCIENTIFIC LITERATURE,=,1.0,CHEMBL,https://pubmed.ncbi.nlm.nih.gov/7703232,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL953,INHIBITOR,Tclin,Homo sapiens,HGNC:2228
erlotinib,1045,Platelet-derived growth factor receptor beta,Kinase,P09619,PDGFRB,PGFRB_HUMAN,5.85,,Kd,Binding constant for PDGFRB kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:8804
erlotinib,1045,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,9.22,,IC50,,WOMBAT-PK,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1079742,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
erlotinib,1045,Vascular endothelial growth factor receptor 3,Kinase,P35916,FLT4,VGFR3_HUMAN,5.68,,Kd,Binding constant for FLT4 kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3767
erlotinib,1045,Focal adhesion kinase 1,Kinase,Q05397,PTK2,FAK1_HUMAN,5.13,,IC50,Inhibition of FAK (unknown origin) assembly preincubated with enzyme followed by GTP addition measured after 20 mins by spectrophotometric analysis,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:9611
estradiol,1057,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,8.83,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
estradiol benzoate,1058,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,5.94,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
estriol succinate,1067,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,6.63,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
ethinylestradiol,1082,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,6.81,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
ethisterone,1084,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,8.78,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
etonogestrel,1110,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,8.23,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
flopropione,1180,Catechol O-methyltransferase,Enzyme,P21964,COMT,COMT_HUMAN,,,,Mechanism of Action,DRUG LABEL,,1.0,DRUG LABEL,http://eisai.jp/medical/products/di/EPI/CSP_C_EPI.pdf,http://eisai.jp/medical/products/di/EPI/CSP_C_EPI.pdf,INHIBITOR,Tclin,Homo sapiens,HGNC:2228
floxacillin,1183,Matrix metalloproteinase-9,Enzyme,P14780,MMP9,MMP9_HUMAN,4.19,,IC50,,WOMBAT-PK,=,,,,,,Tchem,Homo sapiens,HGNC:7176
fluphenazine,1212,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,4.397,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
gefitinib,1282,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,9.4,,Ki,Inhibition of EGFR,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL939,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
gestrinone,1292,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,8.11,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
hexachlorophene,1364,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,6.126,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
hydrocortisone,1388,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,6.2,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
imatinib,1423,Platelet-derived growth factor receptor beta,Kinase,P09619,PDGFRB,PGFRB_HUMAN,7.85,,Kd,Binding constant for PDGFRB kinase domain,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL941,INHIBITOR,Tclin,Homo sapiens,HGNC:8804
imatinib,1423,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.12,,Kd,"Binding constant for EGFR(L747-E749del, A750P) kinase domain",CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
diiodohydroxyquinoline,1457,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.724,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
lapatinib,1548,Platelet-derived growth factor receptor beta,Kinase,P09619,PDGFRB,PGFRB_HUMAN,5.07,,IC50,Inhibition of PDGFRbeta by flash plate based radioactive enzyme assay,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:8804
lapatinib,1548,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,9.04,,Kd,Binding constant for EGFR(G719C) kinase domain,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201179,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
levodopa,1567,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.541,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
levonorgestrel,1572,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,8.91,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
losartan,1610,Platelet glycoprotein VI,Unclassified,Q9HCN6,GP6,GPVI_HUMAN,4.98,,IC50,Antagonist activity at GP6 receptor in human platelet rich plasma assessed as inhibition of collagen-induced platelet aggregation preincubated for 5 mins followed by collagen addition measured after 5 mins by turbidimetric method,CHEMBL,=,,,,,,Tbio,Homo sapiens,HGNC:14388
medroxyprogesterone,1659,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,6.2,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
methyldopa,1762,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.282,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
miconazole,1800,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,4.534,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
mitoxantrone,1821,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.269,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
montelukast,1836,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.495,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
nandrolone,1879,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,6.3,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
nandrolone decanoate,1881,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,6.3,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
nelfinavir,1893,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,4.255,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
niclosamide,1912,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,4.98,,IC50,Inhibition of EGFR after 60 mins by radiometric assay,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
nilotinib,1932,Platelet-derived growth factor receptor beta,Kinase,P09619,PDGFRB,PGFRB_HUMAN,7.8,,Kd,Binding affinity to human PDGFRbeata,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:8804
norethisterone,1962,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,7.97,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
norethindrone acetate,1963,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,7.97,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
perhexiline,2106,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.828,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
prednisolone,2245,Interleukin-6,Cytokine,P05231,IL6,IL6_HUMAN,8.38,,IC50,,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:6018
prednisolone tebutate,2251,Interleukin-6,Cytokine,P05231,IL6,IL6_HUMAN,8.38,,IC50,Fluorescence Polarization Ligand Binding Assay: The glucocorticoid receptor fluorescence polarization ligand binding (GRFP) assay is used to evaluate direct binding of testing compounds to full-length glucocorticoid (GR) protein. Reagents for this assay are purchased from Invitrogen in a test kit. A fluorescent labeled GR ligand is used as a fluorescent tracer and test compounds compete with the fluorescent tracer for GR binding. The change in polarization value in the presence of test compounds is due to binding of test compounds to GR and is used to determine IC50 and relative binding affinity of test compounds for GR.,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:6018
pregnenolone succinate,2256,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,7.15,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
progesterone,2279,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,6.94,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
raloxifene,2351,Interleukin-6,Cytokine,P05231,IL6,IL6_HUMAN,8.05,,IC50,,WOMBAT-PK,=,,,,,,Tclin,Homo sapiens,HGNC:6018
secobarbital,2428,Matrix metalloproteinase-9,Enzyme,P14780,MMP9,MMP9_HUMAN,5.578,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",DRUG MATRIX,=,,,,,,Tchem,Homo sapiens,HGNC:7176
sorafenib,2459,Platelet-derived growth factor receptor beta,Kinase,P09619,PDGFRB,PGFRB_HUMAN,7.43,,Kd,Binding constant for PDGFRB kinase domain,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1336,INHIBITOR,Tclin,Homo sapiens,HGNC:8804
sorafenib,2459,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,8.53,,IC50,Inhibition of EGFR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
sorafenib,2459,Vascular endothelial growth factor receptor 3,Kinase,P35916,FLT4,VGFR3_HUMAN,7.8,,Kd,Average Binding Constant for FLT4; NA=Not Active at 10 uM,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1336,INHIBITOR,Tclin,Homo sapiens,HGNC:3767
sorafenib,2459,Vascular endothelial growth factor receptor 3,Kinase,P35917,Flt4,VGFR3_MOUSE,7.7,,IC50,,IUPHAR,=,,,,,INHIBITOR,,Mus musculus,MGI:95561
sorafenib,2459,Platelet-derived growth factor receptor beta,Kinase,P05622,Pdgfrb,PGFRB_MOUSE,7.24,,IC50,,IUPHAR,=,,,,,INHIBITOR,,Mus musculus,MGI:97531
sulindac,2534,72 kDa type IV collagenase,Enzyme,P08253,MMP2,MMP2_HUMAN,,,,,WOMBAT-PK,,,,,,,Tchem,Homo sapiens,HGNC:7166
suloctidil,2536,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,6.1,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
sunitinib,2544,Platelet-derived growth factor receptor beta,Kinase,P09619,PDGFRB,PGFRB_HUMAN,10.12,,Kd,Binding constant for PDGFRB kinase domain,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1567,INHIBITOR,Tclin,Homo sapiens,HGNC:8804
sunitinib,2544,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,6.07,,Kd,"Binding constant for EGFR(L858R,T790M) kinase domain",CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
sunitinib,2544,Vascular endothelial growth factor receptor 3,Kinase,P35916,FLT4,VGFR3_HUMAN,7.77,,Ki,Binding affinity to VEGFR3 (unknown origin),CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1567,INHIBITOR,Tclin,Homo sapiens,HGNC:3767
sunitinib,2544,Focal adhesion kinase 1,Kinase,Q05397,PTK2,FAK1_HUMAN,6.36,,Kd,Binding constant for PTK2 kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:9611
tacrolimus,2552,Peptidyl-prolyl cis-trans isomerase FKBP10,Enzyme,Q96AY3,FKBP10,FKB10_HUMAN,9.02,,IC50,,WOMBAT-PK,=,,,,,,Tbio,Homo sapiens,HGNC:18169
tamoxifen,2561,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.449,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
terfenadine,2600,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.448,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
testosterone,2607,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,9.2,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
thioridazine,2637,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.531,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
tiludronic acid,2666,72 kDa type IV collagenase,Enzyme,P08253,MMP2,MMP2_HUMAN,5.14,,IC50,Inhibition of APMA-activated recombinant human MMP2 using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured after 2 to 4 hrs by fluorometric assay,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:7166
tolcapone,2697,Catechol O-methyltransferase,Enzyme,P21964,COMT,COMT_HUMAN,9.569,,Ki,,SCIENTIFIC LITERATURE,=,1.0,CHEMBL,https://pubmed.ncbi.nlm.nih.gov/7703232,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1324,INHIBITOR,Tclin,Homo sapiens,HGNC:2228
ubenimex,2787,72 kDa type IV collagenase,Enzyme,P08253,MMP2,MMP2_HUMAN,5.47,,IC50,Inhibition of MMP2 after 30 mins,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:7166
zafirlukast,2855,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.24,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
zoledronic acid,2868,72 kDa type IV collagenase,Enzyme,P08253,MMP2,MMP2_HUMAN,5.15,,IC50,Inhibition of APMA-activated recombinant human MMP2 using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured after 2 to 4 hrs by fluorometric assay,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:7166
zoledronic acid,2868,Matrix metalloproteinase-9,Enzyme,P14780,MMP9,MMP9_HUMAN,4.28,,IC50,Inhibition of MMP9 catalytic domain (unknown origin) using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate incubated for 30 mins prior to substrate addition measured after 2 to 4 hrs by fluorometric assay,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:7176
bithionol,3032,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,6.212,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
estriol,3187,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,6.63,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
estrone,3188,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,8.18,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
oxyquinoline,3290,72 kDa type IV collagenase,Enzyme,P08253,MMP2,MMP2_HUMAN,3.89,,IC50,Inhibition of human recombinant MMP2 after 30 mins,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:7166
oxyquinoline,3290,Catechol O-methyltransferase,Enzyme,P21964,COMT,COMT_HUMAN,5.8,,IC50,Inhibition of c-terminal hexa-His tagged human MB-COMT expressed in HEK293 cell membrane homogenate using norepinephrine as substrate after 1 hr in presence of SAM by MTase glo methyltransferase assay,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:2228
mestanolone,3341,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,8.81,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
mesterolone,3342,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,9.6,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
methyltestosterone,3356,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,8.43,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
pyrithione,3508,Protein-lysine 6-oxidase,Enzyme,P28300,LOX,LYOX_HUMAN,4.48,,IC50,Inhibition of recombinant human LOX expressed in HEK293 cells using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method,CHEMBL,=,,,,,,Tbio,Homo sapiens,HGNC:6664
quercetin,3514,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,6.05,,IC50,Inhibition of EGFR,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
quercetin,3514,72 kDa type IV collagenase,Enzyme,P08253,MMP2,MMP2_HUMAN,5.18,,IC50,Inhibition of human recombinant MMP2 catalytic domain incubated for 20 mins by fluorimetric assay,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:7166
quercetin,3514,Focal adhesion kinase 1,Kinase,Q05397,PTK2,FAK1_HUMAN,5.92,,IC50,Inhibition of FAK (unknown origin),CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:9611
quercetin,3514,Matrix metalloproteinase-9,Enzyme,P14780,MMP9,MMP9_HUMAN,5.79,,IC50,Inhibition of human recombinant MMP9 catalytic domain incubated for 20 mins by fluorimetric assay,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:7176
quercetin,3514,ELAV-like protein 1,Unclassified,Q15717,ELAVL1,ELAV1_HUMAN,5.85,,IC50,Inhibition of ELAV1 (unknown origin)-ARE TNFalpha complex formation after 20 mins by liquid scintillation counting method,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:3312
ruboxistaurin,3533,Platelet-derived growth factor receptor beta,Kinase,P09619,PDGFRB,PGFRB_HUMAN,5.15,,Kd,Average Binding Constant for PDGFRB; NA=Not Active at 10 uM,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:8804
ruboxistaurin,3533,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.29,,Kd,Binding constant for EGFR(E746-A750del) kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
thiram,3601,Protein-lysine 6-oxidase,Enzyme,P28300,LOX,LYOX_HUMAN,5.98,,IC50,Inhibition of recombinant human LOX expressed in HEK293 cells using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method,CHEMBL,=,,,,,,Tbio,Homo sapiens,HGNC:6664
androstanolone,3927,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,9.74,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
tirilazad,4063,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,4.69,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
ascorbic acid,4072,Prolyl 4-hydroxylase subunit alpha-1,Enzyme,P13674,P4HA1,P4HA1_HUMAN,,,,,WOMBAT-PK,,,,,,,Tbio,Homo sapiens,HGNC:8546
ascorbic acid,4072,"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1",Enzyme,Q02809,PLOD1,PLOD1_HUMAN,,,,,WOMBAT-PK,,,,,,,Tbio,Homo sapiens,HGNC:9081
pazopanib,4118,Platelet-derived growth factor receptor beta,Kinase,P09619,PDGFRB,PGFRB_HUMAN,8.7,,Kd,Binding constant for PDGFRB kinase domain,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201733,INHIBITOR,Tclin,Homo sapiens,HGNC:8804
pazopanib,4118,Vascular endothelial growth factor receptor 3,Kinase,P35916,FLT4,VGFR3_HUMAN,7.57,,Kd,Binding constant for FLT4 kinase domain,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201733,INHIBITOR,Tclin,Homo sapiens,HGNC:3767
gentian violet,4138,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,6.325,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
vandetanib,4178,Platelet-derived growth factor receptor beta,Kinase,P09619,PDGFRB,PGFRB_HUMAN,7.06,,Kd,Binding constant for PDGFRB kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:8804
vandetanib,4178,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,8.32,,Kd,Binding constant for EGFR(E746-A750del) kinase domain,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL24828,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
vandetanib,4178,Vascular endothelial growth factor receptor 3,Kinase,P35916,FLT4,VGFR3_HUMAN,6.52,,Kd,Average Binding Constant for FLT4; NA=Not Active at 10 uM,CHEMBL,=,,,,,INHIBITOR,Tclin,Homo sapiens,HGNC:3767
crizotinib,4187,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.57,,Kd,Binding constant for EGFR(G719C) kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
crizotinib,4187,Focal adhesion kinase 1,Kinase,Q05397,PTK2,FAK1_HUMAN,6.51,,Kd,Binding constant for FAK kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:9611
hydroxyprogesterone caproate,4189,Sex hormone-binding globulin,Secreted,P04278,SHBG,SHBG_HUMAN,7.0,,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10839
prazosin,4209,Matrix metalloproteinase-9,Enzyme,P14780,MMP9,MMP9_HUMAN,5.157,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",DRUG MATRIX,=,,,,,,Tchem,Homo sapiens,HGNC:7176
axitinib,4225,Platelet-derived growth factor receptor beta,Kinase,P09619,PDGFRB,PGFRB_HUMAN,9.24,,Kd,Binding constant for PDGFRB kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:8804
axitinib,4225,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.64,,Kd,Binding constant for EGFR(G719C) kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
axitinib,4225,Vascular endothelial growth factor receptor 3,Kinase,P35916,FLT4,VGFR3_HUMAN,6.77,,Kd,Binding constant for FLT4 kinase domain,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1289926,INHIBITOR,Tclin,Homo sapiens,HGNC:3767
afatinib,4318,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,10.0,,Kd,Binding constant for EGFR(G719C) kinase domain,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1173655,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
zinc chloride,4344,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.66,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
bosutinib,4359,Platelet-derived growth factor receptor beta,Kinase,P09619,PDGFRB,PGFRB_HUMAN,6.7,,Kd,Binding constant for PDGFRB kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:8804
bosutinib,4359,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,7.74,,Kd,Binding constant for EGFR(E746-A750del) kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
bosutinib,4359,Focal adhesion kinase 1,Kinase,Q05397,PTK2,FAK1_HUMAN,6.24,,Kd,Binding constant for FAK kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:9611
cisplatin,4392,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.582,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
colistin,4425,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.824,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
regorafenib,4654,Platelet-derived growth factor receptor beta,Kinase,P09619,PDGFRB,PGFRB_HUMAN,8.82,,IC50,Inhibition of PDGFR beta (561 to 1106 residues) (unknown origin),CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:8804
regorafenib,4654,Vascular endothelial growth factor receptor 3,Kinase,P35917,Flt4,VGFR3_MOUSE,8.82,,IC50,Inhibition of mouse VEGFR-3 (818 to 1363 residues),CHEMBL,=,,,,,,,Mus musculus,MGI:95561
regorafenib,4654,Platelet-derived growth factor receptor beta,Kinase,P09619,PDGFRB,PGFRB_HUMAN,8.82,,IC50,Inhibition of PDGFR beta (561 to 1106 residues) (unknown origin),CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:8804
regorafenib,4654,Vascular endothelial growth factor receptor 3,Kinase,P35917,Flt4,VGFR3_MOUSE,8.82,,IC50,Inhibition of mouse VEGFR-3 (818 to 1363 residues),CHEMBL,=,,,,,,,Mus musculus,MGI:95561
sodium aurothiomalate,4706,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.624,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
cabozantinib,4715,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,6.65,,IC50,Inhibition of EGFR (unknown origin) by HTRF method,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
cabozantinib,4715,Vascular endothelial growth factor receptor 3,Kinase,P35916,FLT4,VGFR3_HUMAN,8.22,,IC50,Inhibition of VEGFR3 (unknown origin),CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3767
cabozantinib,4715,Vascular endothelial growth factor receptor 3,Kinase,P35916,FLT4,VGFR3_HUMAN,8.22,,IC50,Inhibition of VEGFR3 (unknown origin),CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3767
ponatinib,4716,Platelet-derived growth factor receptor beta,Kinase,P09619,PDGFRB,PGFRB_HUMAN,8.92,,IC50,"Inhibition of recombinant PDGFRbeta (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 60 mins by ELISA",CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:8804
dimethyl fumarate,4757,Kelch-like ECH-associated protein 1,Cytosolic other,Q14145,KEAP1,KEAP1_HUMAN,,,,Mechanism of Action; CHEMBL2069156; SINGLE PROTEIN,CHEMBL,,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2107333,INHIBITOR,Tclin,Homo sapiens,HGNC:23177
ibrutinib,4810,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,8.25,,IC50,Inhibition of ErbB1 relative to control,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
ceritinib,4866,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,6.05,,IC50,Inhibition of EGFR (unknown origin) after 60 mins,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
nintedanib,4903,Platelet-derived growth factor receptor beta,Kinase,P09619,PDGFRB,PGFRB_HUMAN,7.82,,Kd,Binding constant for PDGFRB kinase domain,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL502835,INHIBITOR,Tclin,Homo sapiens,HGNC:8804
nintedanib,4903,Focal adhesion kinase 1,Kinase,Q05397,PTK2,FAK1_HUMAN,6.68,,Kd,Binding constant for FAK kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:9611
nintedanib,4903,Vascular endothelial growth factor receptor 3,Kinase,P35916,FLT4,VGFR3_HUMAN,8.301,,IC50,,SCIENTIFIC LITERATURE,=,1.0,SCIENTIFIC LITERATURE,https://pubmed.ncbi.nlm.nih.gov/19522465,https://pubmed.ncbi.nlm.nih.gov/19522465,INHIBITOR,Tclin,Homo sapiens,HGNC:3767
lenvatinib,4942,Platelet-derived growth factor receptor beta,Kinase,P09619,PDGFRB,PGFRB_HUMAN,7.409,,IC50,in vitro kinase activity at 1uM ATP,SCIENTIFIC LITERATURE,=,,,https://pubmed.ncbi.nlm.nih.gov/17943726,,INHIBITOR,Tclin,Homo sapiens,HGNC:8804
lenvatinib,4942,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.187,,IC50,in vitro kinase activity at 1uM ATP,SCIENTIFIC LITERATURE,=,,,https://pubmed.ncbi.nlm.nih.gov/17943726,,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
lenvatinib,4942,Vascular endothelial growth factor receptor 3,Kinase,P35916,FLT4,VGFR3_HUMAN,8.284,,IC50,in vitro kinase activity at 1uM ATP,SCIENTIFIC LITERATURE,=,1.0,DRUG LABEL,https://pubmed.ncbi.nlm.nih.gov/17943726,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206947s000lbl.pdf,INHIBITOR,Tclin,Homo sapiens,HGNC:3767
cetuximab,4954,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,9.41,,Kd,,IUPHAR,=,1.0,DRUG LABEL,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125084s063lbl.pdf,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125084s063lbl.pdf,ANTIBODY BINDING,Tclin,Homo sapiens,HGNC:3236
panitumumab,4955,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,10.3,,Kd,,IUPHAR,=,1.0,DRUG LABEL,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125147s200lbl.pdf,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125147s200lbl.pdf,AGONIST,Tclin,Homo sapiens,HGNC:3236
siltuximab,4977,Interleukin-6,Cytokine,P05231,IL6,IL6_HUMAN,,,,Mechanism of Action,DRUG LABEL,,1.0,DRUG LABEL,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125496s000lbl.pdf,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125496s000lbl.pdf,ANTIBODY BINDING,Tclin,Homo sapiens,HGNC:6018
osimertinib,5062,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,7.824,,IC50,Inhibition of EGFR phosphorylation in double mutant cell line H1975,SCIENTIFIC LITERATURE,=,1.0,DRUG LABEL,https://pubmed.ncbi.nlm.nih.gov/25271963,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208065s000lbl.pdf,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
necitumumab,5071,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,9.49,,Kd,Binding affinity of whole IMC-11F8 IgG using BIAcore sensor technology.,IUPHAR,=,1.0,DRUG LABEL,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125547s000lbl.pdf,ANTIBODY BINDING,Tclin,Homo sapiens,HGNC:3236
chromic chloride,5118,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.53,,IC50,,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
opicapone,5143,Catechol O-methyltransferase,Enzyme,O88587,Comt,COMT_MOUSE,8.82,,Ki,,IUPHAR,=,,,,,INHIBITOR,,Mus musculus,MGI:88470
opicapone,5143,Catechol O-methyltransferase,Enzyme,P21964,COMT,COMT_HUMAN,9.0,,Ki,,SCIENTIFIC LITERATURE,=,1.0,SCIENTIFIC LITERATURE,https://pubmed.ncbi.nlm.nih.gov/24847974,https://pubmed.ncbi.nlm.nih.gov/24847974,INHIBITOR,Tclin,Homo sapiens,HGNC:2228
icotinib,5209,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,8.699,,IC50,,SCIENTIFIC LITERATURE,=,1.0,SCIENTIFIC LITERATURE,https://pubmed.ncbi.nlm.nih.gov/22959248,https://pubmed.ncbi.nlm.nih.gov/22088449,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
olmutinib,5210,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,8.036,,IC50,HCC827 cells expressing EGFR(DEL19),SCIENTIFIC LITERATURE,=,1.0,SCIENTIFIC LITERATURE,https://pubmed.ncbi.nlm.nih.gov/27357069,https://pubmed.ncbi.nlm.nih.gov/27357069,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
midostaurin,5231,Platelet-derived growth factor receptor beta,Kinase,P09619,PDGFRB,PGFRB_HUMAN,6.96,,Kd,Binding constant for PDGFRB kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:8804
midostaurin,5231,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,8.06,,Kd,"Binding constant for EGFR(L858R,T790M) kinase domain",CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
midostaurin,5231,Vascular endothelial growth factor receptor 3,Kinase,P35916,FLT4,VGFR3_HUMAN,6.17,,Kd,Binding constant for FLT4 kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3767
brigatinib,5233,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,7.174,,IC50,,SCIENTIFIC LITERATURE,=,,,https://pubmed.ncbi.nlm.nih.gov/27780853,,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
neratinib,5252,Focal adhesion kinase 1,Kinase,Q05397,PTK2,FAK1_HUMAN,5.72,,Kd,Binding constant for FAK kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:9611
neratinib,5252,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,7.036,,IC50,,SCIENTIFIC LITERATURE,=,1.0,DRUG LABEL,https://pubmed.ncbi.nlm.nih.gov/15715478,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
tivozanib,5258,Platelet-derived growth factor receptor beta,Kinase,P09619,PDGFRB,PGFRB_HUMAN,8.764,,IC50,,SCIENTIFIC LITERATURE,=,,,https://pubmed.ncbi.nlm.nih.gov/16982756,,INHIBITOR,Tclin,Homo sapiens,HGNC:8804
tivozanib,5258,Vascular endothelial growth factor receptor 3,Kinase,P35916,FLT4,VGFR3_HUMAN,9.62,,IC50,,SCIENTIFIC LITERATURE,=,1.0,DRUG LABEL,https://pubmed.ncbi.nlm.nih.gov/16982756,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004131/WC500239033.pdf,INHIBITOR,Tclin,Homo sapiens,HGNC:3767
dacomitinib,5297,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,8.222,,IC50,ELISA-Based erbB Kinase Assay with 20 uM [ATP],SCIENTIFIC LITERATURE,=,1.0,DRUG LABEL,https://pubmed.ncbi.nlm.nih.gov/30506139,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
lorlatinib,5302,Focal adhesion kinase 1,Kinase,Q05397,PTK2,FAK1_HUMAN,7.77,,IC50,,SCIENTIFIC LITERATURE,=,1.0,DRUG LABEL,https://pubmed.ncbi.nlm.nih.gov/25733882,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf,INHIBITOR,Tclin,Homo sapiens,HGNC:9611
caplacizumab,5308,von Willebrand factor,Unclassified,P04275,VWF,VWF_HUMAN,8.509,,Kd,,IUPHAR,=,1.0,DRUG LABEL,,https://pubmed.ncbi.nlm.nih.gov/30298461,ANTIBODY BINDING,Tclin,Homo sapiens,HGNC:12726
quizartinib,5341,Platelet-derived growth factor receptor beta,Kinase,P09619,PDGFRB,PGFRB_HUMAN,8.8,,Kd,Binding affinity to PDGFRbeta,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:8804
quizartinib,5341,Vascular endothelial growth factor receptor 3,Kinase,P35916,FLT4,VGFR3_HUMAN,7.39,,Kd,Binding affinity to FLT4,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3767
entrectinib,5345,Focal adhesion kinase 1,Kinase,Q05397,PTK2,FAK1_HUMAN,6.85,,IC50,Inhibition of FAK (unknown origin) in presence of gamma33-ATP,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:9611
fedratinib,5347,Platelet-derived growth factor receptor beta,Kinase,P09619,PDGFRB,PGFRB_HUMAN,7.35,,Kd,Binding constant for PDGFRB kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:8804
fedratinib,5347,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,6.24,,Kd,Binding constant for EGFR(T790M) kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
fedratinib,5347,Vascular endothelial growth factor receptor 3,Kinase,P35916,FLT4,VGFR3_HUMAN,5.7,,Kd,Binding constant for FLT4 kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3767
fedratinib,5347,Focal adhesion kinase 1,Kinase,Q05397,PTK2,FAK1_HUMAN,7.38,,Kd,Binding constant for FAK kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:9611
selumetinib,5388,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.66,,Kd,Binding constant for EGFR(T790M) kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
tucatinib,5389,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,6.35,,IC50,Inhibition of enzyme activity in a biochemical assay.,IUPHAR,=,,,,,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
ripretinib,5394,Platelet-derived growth factor receptor beta,Kinase,P09619,PDGFRB,PGFRB_HUMAN,8.05,,IC50,In vitro kinase binding assay,DRUG LABEL,=,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213973Orig1s000MultidisciplineR.pdf,,INHIBITOR,Tclin,Homo sapiens,HGNC:8804
pralsetinib,5412,Platelet-derived growth factor receptor beta,Kinase,P09619,PDGFRB,PGFRB_HUMAN,7.0,,IC50,,DRUG LABEL,=,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213721Orig1s000MultidisciplineR.pdf,,INHIBITOR,Tclin,Homo sapiens,HGNC:8804
filgotinib,5419,Vascular endothelial growth factor receptor 3,Kinase,P35916,FLT4,VGFR3_HUMAN,6.56,,IC50,Inhibition of human FLT4 (unknown origin),CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3767
filgotinib,5419,Vascular endothelial growth factor receptor 3,Kinase,P35916,FLT4,VGFR3_HUMAN,6.56,,IC50,Inhibition of human FLT4 (unknown origin),CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3767
infigratinib,5459,Vascular endothelial growth factor receptor 3,Kinase,P35916,FLT4,VGFR3_HUMAN,5.68,,IC50,Inhibition of VEGFR3 juxtamembrane domain-mediated proliferation of mouse BAF3 cells transformed with TEL-Kinase construct,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3767
infigratinib,5459,Vascular endothelial growth factor receptor 3,Kinase,P35916,FLT4,VGFR3_HUMAN,5.68,,IC50,Inhibition of VEGFR3 juxtamembrane domain-mediated proliferation of mouse BAF3 cells transformed with TEL-Kinase construct,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3767
